VitaNova Life Sciences (VNOV) Long-Term Deferred Tax (2018 - 2026)

VitaNova Life Sciences' (VNOV) quarterly Long-Term Deferred Tax came in at $16038.0 in Q2 2026, down 83.66% on a QoQ basis from $98161.0 in Q1 2026.

VitaNova Life Sciences (VNOV) Long-Term Deferred Tax (2018 - 2026) Analysis & Trends

VitaNova Life Sciences (VNOV) has 9 years of Long-Term Deferred Tax data on file, last reported at $16038.0 in Q2 2026.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $16038.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $16038.0 (changed N/A YoY) and the FY2026 annual result came in at $16038.0, changed N/A from the prior year.
Long-Term Deferred Tax eased to $16038.0 in Q2 2026, from $98161.0 in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $156912.0 in Q4 2023 to a low of $8632.0 in Q4 2022.
A 5-year average of $76354.4 and a median of $75881.5 in 2022 frame the typical range for Long-Term Deferred Tax.
Annual changes were most pronounced in 2022 — Long-Term Deferred Tax slumped 89.45% — and 2023, when it surged 1717.79%.
Tracing VNOV's Long-Term Deferred Tax over 5 years: stood at $8632.0 in 2022, then surged by 1717.79% to $156912.0 in 2023, then sank by 49.73% to $78887.0 in 2024, then surged by 87.52% to $147929.0 in 2025, then sank by 89.16% to $16038.0 in 2026.
The last three Long-Term Deferred Tax figures came in at $16038.0 (Q2 2026), $98161.0 (Q1 2026), and $147929.0 (Q4 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Mckesson	102.57 Bn	97.41 Bn	3.69 Bn
2	Cencora	61.35 Bn	58.53 Bn	3.61 Bn
3	Cardinal Health	54.15 Bn	49.30 Bn	2.56 Bn
4	Henry Schein	10.05 Bn	9.89 Bn	1.10 Bn
5	Akso Health	671.90 Mn	671.70 Mn	-
6	Edap Tms	154.62 Mn	133.07 Mn	7.34 Mn
7	Accendra Health	90.69 Mn	83.04 Mn	263.41 Mn
8	111	31.31 Mn	-27.44 Mn	18.18 Mn
9	Cosmos Health	13.28 Mn	10.84 Mn	1.51 Mn
10	VitaNova Life Sciences	11.51 Mn	9.91 Mn	264,662.00

Download Data